natgillin/translations-raw huggingface dataset:
- Any medicine containing magnesium or aluminium such as antacids for indigestion, or any medicine containing iron or zinc, medicine containing didanosine or medicine containing sucralfate to treat gastrointestinal disorders can reduce the action of [Invented name] tablets.
- Zdravila, ki vsebujejo magnezij ali aluminij (npr. antacidi za zdravljenje prebavnih težav ali katerakoli zdravila, ki vsebujejo železo ali cink, didanozin, sukralfat za zdravljenje prebavnih motenj), lahko zmanjšajo delovanje tablet [izmišljeno ime].
Higher plasma concentrations are observed in healthy volunteers with low body weight (such as women) and in elderly volunteers.
Pri zdravih prostovoljcih z manjšo telesno maso (npr. ženskah) in starejših prostovoljcih opažamo večje plazemske koncentracije.
You should avoid prolonged exposure to sunlight or strong sunlight and should not use a sunbed or any other UV lamp while taking [Invented name].
Med jemanjem zdravila [izmišljeno ime] se morate izogibati daljšemu izpostavljanju sončni svetlobi ali močni sončni svetlobi in ne smete uporabljati solarija ali drugih UV svetilk.
Avalox film-coated tablets contain 400 mg moxifloxacin as hydrochloride.
Avalox - filmsko obložene tablete vsebujejo 400 mg moksifloksacina v obliki klorida.
- If you or any member of your family have glucose-6-phosphate dehydrogenase deficiency (a rare hereditary disease), inform your doctor, who will advise whether [Invented name] is suitable for you.
- Če imate vi ali katerikoli član vaše družine pomanjkanje glukoza-6-fosfat dehidrogenaze (redko prirojeno bolezen), o tem obvestite svojega zdravnika, ki vam bo svetoval ali je [izmišljeno ime] primerno zdravilo za vas.
EUCAST clinical MIC breakpoints for moxifloxacin (31.01.2006): Organism
Klinične mejne vrednosti MIK za moksifloksacin (EUCAST) (31. 01. 2006): organizem občutljiva odporna
The bactericidal action of moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair.
Moksifloksacin deluje baktericidno tako, da zavira oba tipa topoizomeraz II (girazo DNK in topoizomerazo IV), ki sta potrebni pri podvajanju, prepisovanju in obnavljanju bakterijske DNK.
- If you have a complicated infection of the female upper genital tract (e.g. associated with an abscess of the fallopian tubes and ovaries or of the pelvis), for which your doctor considers an intravenous treatment necessary, treatment with [Invented name] tablets is not appropriate.
- Če imate zapleteno okužbo ženskih notranjih spolovil (npr. s spremljajočim abscesom v jajcevodih in jajčnikih ali medenici), za katero vaš zdravnik oceni, da je potrebno intravensko zdravljenje, zdravljenje s tabletami [izmišljeno ime] ni primerno.
Aerobic Gram-positive micro-organisms Gardnerella vaginalis
splošno občutljive vrste aerobni, po Gramu pozitivni mikroorganizmi Gardnerella vaginalis
In vitro resistance to moxifloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Moxifloxacin is a poor substrate for active efflux mechanisms in Gram-positive organisms.
Odpornost proti moksifloksacinu in vitro je pridobljena postopoma in sicer s tarčnimi mutacijami v obeh tipih topoizomeraz II, girazi DNK in topoizomerazi IV. Moksifloksacin je nezadosten substrat za mehanizme aktivnega prehoda v po Gramu pozitivnih organizmih.
- For patients with complicated pelvic inflammatory disease (e.g. associated with a tubo-ovarian or pelvic abscess), for whom an intravenous treatment is considered necessary, treatment with [Invented name] 400 mg film-coated tablets is not recommended.
- Pri bolnikih z zapleteno medenično vnetno boleznijo (npr. s spremljajočim tuboovarijskim ali medeničnim abscesom), pri katerih je potrebno intravensko zdravljenje, se zdravljenja z zdravilom [izmišljeno ime] 400 mg filmsko obložene tablete ne priporoča.
Moxifloxacin therapy may give false negative culture results for Mycobacterium spp.
Zaradi zdravljenja z moksifloksacinom so lahko rezultati testa kulture pri Mycobacterium spp.
Driving and using machines [Invented name] may make you feel dizzy or light-headed.
Vpliv na sposobnost upravljanja vozil in strojev [izmišljeno ime] lahko povzroči vrtoglavico ali omotico.
If you are currently taking any medicine that decrease your blood potassium levels, consult your doctor before taking [Invented name].
Če jemljete druga zdravila, ki zmanjšajo vrednost kalija v krvi, se posvetujte s svojim zdravnikom preden vzamete [izmišljeno ime].
It appears that the C8-methoxy moiety contributes to enhanced activity and lower selection of resistant mutants of Gram-positive bacteria compared to the C8-H moiety.
Zdi se, da C8-metoksi skupina (v primerjavi s C8-H-skupino) prispeva k večji dejavnosti in manjši selekciji odpornih mutantov po Gramu pozitivnih bakterij.
- Pelvic inflammatory disease may be caused by fluoroquinolone resistant Neisseria gonorrhoeae.
- Medenično vnetno bolezen lahko povzroči proti fluorokinolonom odporna bakterija Neisseria gonorrhoeae.
If you do not take your tablet on one day, take your normal dose (one tablet) on the next day.
Če ne vzamete tablete istega dne, vzemite običajni odmerek (eno tableto) naslednji dan. Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
There is insufficient data in patients with impaired liver function (see section 4.3).
Podatki, s katerimi bi podprli uporabo moksifloksacina pri bolnikih z oslabljeno jetrno funkcijo, so pomanjkljivi (glejte poglavje 4.3).
pseudomembranous colitis) has been reported in association with the use of broad spectrum antibiotics including moxifloxacin; therefore it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of moxifloxacin.
- Ker so pri uporabi antibiotikov širokega spektra, vključno z moksifloksacinom, poročali o kolitisu, povezanim z antibiotičnim zdravljenjem (tudi psevdomembranskem kolitisu), je pomembno, da to diagnozo upoštevamo pri bolnikih, pri katerih se huda driska pojavi med uporabo moksifloksacina ali po njej.
- Tendon inflammation and rupture may occur with quinolone therapy including moxifloxacin, particularly in elderly patients and in those treated concurrently with corticosteroids.
- Med zdravljenjem s kinoloni, vključno z moksifloksacinom, se lahko pojavi vnetje in ruptura kit, predvsem pri starejših bolnikih in tistih, ki se sočasno zdravijo s kortikosteroidi.
Before you take [Invented name] ..., Take special care ...).
Kaj morate vedeti, preden boste vzeli zdravilo [izmišljeno ime]... , Bodite posebno pozorni...).
Clinical and Laboratory Standards Institute™ (CLSI), formerly NCCLS breakpoints are presented in the below table for MIC testing (mg/l) or disc diffusion testing (zone diameter [mm]) using a 5-µg moxifloxacin disc.
Mejne vrednosti Kliničnih in laboratorijskih standardnih predpisovTM (CLSI-Clinical and Laboratory Standards InstituteTM) (prej mejne vrednosti NCCLS) so predstavljene v spodnji preglednici glede na preskušanje minimalnih inhibicijskih koncentracij (mg/l) ali preskušanje z disk-difuzijsko metodo (premer pasu (mm)), uporaba 5-mikrogramskega diska moksifloksacina.
This is because [Invented name] can cause a certain change on the ECG, that is a prolongation of the QT-interval i.e delayed conduction of electrical signals.
[izmišljeno ime] lahko povzroči določene spremembe v EKG-ju (npr. podaljšanje QT dobe - t.j.
Pharmacodynamic investigations have demonstrated that moxifloxacin exhibits a concentration dependent killing rate.
S farmakodinamičnimi študijami so dokazali, da je stopnja baktericidnosti moksifloksacina odvisna od njegove koncentracije.
[Invented name] 400 mg film-coated tablets are indicated for the treatment of the above infections if they are caused by bacteria susceptible to moxifloxacin.
Filmsko obložene tablete [izmišljeno ime] 400 mg so indicirane za zdravljenje naštetih okužb, če jih povzročajo bakterije, občutljive za moksifloksacin.
Species for which acquired resistance may be a problem Aerobic Gram-positive micro-organisms Staphylococcus aureus (methicillin-resistant)+
Mycoplasma pneumoniae* vrste, pri katerih je pridobljena odpornost lahko vprašljiva aerobni, po Gramu pozitivni mikroorganizmi Staphylococcus aureus (odporni proti meticilinu)+
Dosage (adults) One 400 mg film-coated tablet once daily.
Odmerjanje (odrasli) Ena 400 mg filmsko obložena tableta enkrat na dan.
Before taking [Invented name] 400 mg film-coated tablets - [Invented name] can change your heart's ECG.
Pred jemanjem zdravila [izmišljeno ime] 400 mg filmsko obložene tablete - [izmišljeno ime] lahko vpliva na vaš EKG srca.
Objections and concerns over the efficacy and safety of Avalox in the proposed indication were raised during the Mutual Recognition variation procedure.
Med postopkom medsebojnega priznavanja za prijavljeno spremembo so bili izraženi ugovori in pomisleki glede učinkovitosti in varnosti zdravila Avalox pri predlagani indikaciji.
The prevalence of acquired resistance may vary geographically and with time for selected species and local information of resistance is desirable, particularly when treating severe infections.
Prevalenca pridobljene odpornosti se lahko za izbrane vrste razlikuje geografsko in časovno.
by suppression of mycobacterial growth.
lažno negativni zaradi supresije rasti mikobakterije.
- The Committee considered that robust data is available showing the efficacy of Avalox in the indication “Treatment of mild to moderate pelvic inflammatory disease (PID), i.e. infections of upper genital tract, including salpingitis and endometritis” , however due to emerging resistance of N. gonorrhoeae, moxifloxacin should not be used in empirical monotherapy, unless moxifloxacinresistant N. gonorrhoeae can be excluded.
- Odbor je sklenil, da so na voljo trdni podatki, ki dokazujejo učinkovitost zdravila Avalox pri indikaciji „zdravljenje blagih do zmernih pelvičnih vnetnih bolezni, tj. okužb zgornjega genitalnega trakta, vključno s salpingitisom in endometritisom“, vendar pa se moksifloksacin zaradi pojava odpornosti na N. gonorrhoeae ne sme uporabljati v empirični monoterapiji, razen če je mogoče izključiti N. gonorrhoeae, odporno na moksifloksacin.
#ESBL-producing strains are commonly resistant to fluoroquinolones +Resistance rate > 50% in one or more countries
+stopnja odpornosti > 50 % v eni ali več državah
For [Invented name] be aware of the following: - If you are taking [Invented name] and other medicines that affect your heart there is an increased risk for altering your heartbeat.
Pri jemanju zdravila [izmišljeno ime] bodite pozorni: - Če jemljete [izmišljeno ime] in druga zdravila, ki vplivajo na srce, obstaja zvečano tveganje za spremembe srčnega utripa.
If you take more than the prescribed one tablet a day, seek medical advice immediately and, if possible, take any remaining tablets, the packaging or this leaflet with you to show the doctor or pharmacist what you have taken.
Če je mogoče, vzemite preostale tablete, škatlo ali to navodilo za uporabo s seboj k zdravniku ali farmacevtu ter mu pokažite katero zdravilo ste zaužili.
were reduced, as were the anaerobes Bacteroides vulgatus, Bifidobacterium spp., Eubacterium spp., and Peptostreptococcus spp.. For Bacteroides fragilis there was an increase.
se je zmanjšalo, prav tako tudi število anaerobov Bacteroides vulgatus, Bifidobacterium spp., Eubacterium spp.
Peak and trough plasma concentrations at steady-state (400 mg once daily) were 3.2 and 0.6 mg/l, respectively.
Največja plazemska koncentracija pri dinamičnem ravnovesju (400 mg enkrat na dan) je 3,2 mg/l, najmanjša pa 0,6 mg/l.
Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to moxifloxacin, in the form of QT prolongation.
Tako v predkliničnih študijah kot tudi v študijah pri ljudeh so med zdravljenjem z moksifloksacinom opazili spremembe elektrofiziologije srca (v obliki podaljšane QT dobe).
Other special populations No adjustment of dosage is required in the elderly and in patients with low bodyweight.
Druge posebne skupine Starejšim bolnikom in bolnikom z majhno telesno maso odmerka ni treba prilagajati.
- If you were born with or have had any condition with certain abnormal electrocardiogram (ECG, electrical recording of the heart) changes, have salt imbalance in the blood, especially low concentrations of potassium in the blood (hypokalaemia) which are currently not corrected by treatment, have a very slow heart rate (bradycardia), have a weak heart (heart failure), have a history of abnormal heart rhythms (arrhythmias), or you are taking other medicines that result in certain abnormal ECG changes (see section Taking other medicines).
Možni neželeni učinki), - če imate prirojene motnje ali kakršnekoli druge spremembe v elektrokardiogramu (EKG, zapis električnih potencialov srca), če se je pri vas porušilo ravnovesje soli v krvi, še posebej, če imate nezdravljeno nizko koncentracijo kalija v krvi (hipokaliemijo), če imate zelo počasen srčni utrip (bradikardija), če imate oslabelo srce (srčno popuščanje), če ste že imeli motnje srčnega ritma (aritmije), ali če jemljete druga zdravila, ki povzročajo določene motnje v EKG-ju (glejte poglavje Jemanje drugih zdravil).
Moxifloxacin undergoes Phase II biotransformation and is excreted via renal and biliary/faecal pathways as unchanged drug as well as in the form of a sulpho-compound (M1) and a glucuronide (M2).
fazi, izloča pa se z urinom in žolčem/blatom, in sicer kot nespremenjeno zdravilo, pa tudi v obliki žveplove spojine (M1) in glukuronida (M2).
The CHMP considered that QT-prolongation in PID should however be carefully addressed by the MAH in future PSURs.
Vendar pa je CHMP menil, da mora imetnik dovoljenja za promet z zdravilom podaljšanje intervala QT pri pelvičnih vnetnih boleznih temeljito obravnavati v prihodnjih periodičnih posodobitvenih varnostnih poročilih (PSUR).
Clinical and Laboratory Standards Institute™ (CLSI) MIC and disc diffusion breakpoints for Staphylococcus spp.
Mejne vrednosti Kliničnih in laboratorijskih standardnih predpisovTM (CLSI-Clinical and Laboratory Standards InstituteTM) glede na preskušanje MIK in disk-difuzijsko metodo za Staphylococcus spp.
When taking [Invented name] 400 mg film-coated tablets - The risk of cardiac abnormalities may increase with increase of the dose.
Med jemanjem zdravila [izmišljeno ime] 400 mg filmsko obložene tablete - Tveganje za srčne nepravilnosti se lahko zveča z zvečanjem odmerka, zato morate upoštevati odmerjanje.
- For the treatment of mild to moderate infections of the female upper genital tract your doctor should prescribe another antibiotic in addition to [Invented name].
- Za zdravljenje blagih do zmernih okužb ženskih notranjih spolovil vam bo zdravnik predpisal v kombinaciji s tabletami [izmišljeno ime] še drug antibiotik.
It became evident during the course of the variation preceding this referral that an empirical therapy of PID with moxifloxacin should be avoided due to the high portion of N. gonorrhoeae being resistant to moxifloxacin and other quinolones.
Med postopkom za odobritev spremembe pred tem postopkom napotitve se je izkazalo, da se je treba izogibati empiričnemu zdravljenju pelvečnih vnetnih bolezni z moksifloksacinom zaradi velikega deleža N. gonorrhoeae, odpornih na moksifloksacin in druge kinolone.
BayHealth - Comercialização de Produtos Farmacêuticos Unipessoal, Lda.
PT - Portugalska BayHealth - Comercialização de Produtos Farmacêuticos
- If you suffer from epilepsy or a condition which makes you likely to have convulsions, consult your doctor before taking [Invented name].
- Če imate epilepsijo ali stanja, ki povzročajo krče, se morate pred začetkom jemanja zdravila [izmišljeno ime] posvetovati s svojim zdravnikom.
- Cases of fulminant hepatitis potentially leading to life-threatening liver failure have been reported with moxifloxacin (see section 4.8).
- V povezavi z moksifloksacinom so poročali o primerih fulminantnega hepatitisa, ki lahko povzroči smrtno nevarno jetrno odpoved (glejte poglavje 4.8).
Moxifloxacin has in vitro activity against a wide range of Gram-positive and Gram-negative pathogens.
In vitro deluje moksifloksacin na širok spekter po Gramu pozitivnih in po Gramu negativnih patogenov.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking [Invented name].
Če vam je zdravnik povedal, da imate intoleranco za nekatere sladkorje, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Bayer HealthCare AG 51 368 Leverkusen Germany
Bayer HealthCare AG 51 368 Leverkusen Nemčija
[Invented name] tablets are not sufficient for sole therapy of this kind of infections and therefore another antibiotic in addition to [Invented name] tablets should be prescribed by your doctor for the treatment of infections of the female upper genital tract (see section 2.
Tablete [izmišljeno ime] niso primerne za zdravljenje teh okužb v monoterapiji, zato bo zdravnik za zdravljenje okužb ženskih notranjih spolovil predpisal v kombinaciji s tabletami [izmišljeno ime] še drug antibiotik (glejte poglavje 2.
WHAT [INVENTED NAME] 400 MG FILM-COATED TABLETS ARE AND WHAT THEY ARE USED FOR
KAJ JE ZDRAVILO [IZMIŠLJENO IME] 400 MG FILMSKO OBLOŽENE TABLETE IN ZA KAJ GA UPORABLJAMO
- If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.
- Če se pojavijo motnje vida ali kakršnekoli očesne spremembe, mora bolnik takoj obiskati oftalmologa.
[Invented name] works by killing bacteria that cause infections, if they are caused by bacteria that are susceptible to the active ingredient moxifloxacin.
[izmišljeno ime] uničuje bakterije, ki povzročajo okužbe in so občutljive za zdravilno učinkovino moksifloksacin.
If you stop taking this medicine too soon your infection may not be completely cured, the infection may return or your condition may get worse, and you may also create a bacterial resistance to the antibiotic.
Okužba se lahko ponovi ali se stanje poslabša in pri vas se lahko razvije odpornost bakterij na antibiotike.
At the first sign of any pain or inflammation you should stop taking [Invented name], rest the affected limb and consult your doctor immediately.
Takoj ko se pojavijo bolečine ali vnetje, morate prenehati jemati [izmišljeno ime], prizadeti ud pa mora mirovati.
At the first sign of pain or inflammation, patients should discontinue treatment with moxifloxacin and rest the affected limb(s).
Takoj ko se pojavijo bolečine ali vnetje, morajo bolniki zdravljenje z moksifloksacinom prekiniti, prizadeti ud(i) pa mora(jo) mirovati.
The CHMP considered that due to the emergence of fluoroquinolone-resistant N. gonorrhoeae strains moxifloxacin should not be used in empirical monotherapy of mild to moderate PID, unless a resistance against moxifloxacin can be ruled out.
CHMP je menil, da se moksifloksacin zaradi pojava na fluorokinolone odpornih sevov N. gonorrhoeae ne sme uporabljati v empirični monoterapiji blagih do zmernih pelvičnih vnetnih bolezni, razen če je mogoče izključiti odpornost na moksifloksacin.
No adjustment of dosage is required in patients with mild to severely impaired renal function or in patients on chronic dialysis i.e. haemodialysis and continuous ambulatory peritoneal dialysis (see section 5.2 for more details).
Bolnikom z blago do hudo oslabljeno ledvično funkcijo ali bolnikom na kronični dializi (hemodializi in kontinuirani ambulantni peritonealni dializi) odmerka ni treba prilagajati (za podrobnosti glejte poglavje 5.2).
[Invented name] 400 mg film-coated tablets are not recommended for use in monotherapy of mild to moderate pelvic inflammatory disease but should be given in combination with another appropriate antibacterial agent (e.g. a cephalosporin) due to increasing moxifloxacin resistance of Neisseria gonorrhoeae unless moxifloxacin-resistant Neisseria gonorrhoeae can be excluded (see sections 4.4 and 5.1).
Pri blagih do zmernih medeničnih vnetnih boleznih zdravila [izmišljeno ime] 400 mg filmsko obložene tablete ni priporočljivo uporabljati v monoterapiji, ampak ga je treba zaradi naraščajoče odpornosti bakterije Neisseria gonorrhoeae proti moksifloksacinu predpisati v kombinaciji z drugim ustreznim protibakterijskim zdravilom (npr. s cefalosporinom), razen v primeru, ko je mogoče izključiti prisotnost proti moksifloksacinu odporne bakterije Neisseria gonorrhoeae (glejte poglavji 4.4 in 5.1).
- Due to adverse effects on the cartilage in juvenile animals (see section 5.3) the use of moxifloxacin in children and adolescents < 18 years is contraindicated (see section 4.3).
- Uporaba moksifloksacina je kontraindicirana pri otrocih in mladostnikih do 18. leta starosti (glejte poglavje 4.3) zaradi njegovih neželenih učinkov na hrustanec pri živalskih mladičih (glejte poglavje 5.3).
Pharmacokinetics are linear in the range of 50 - 800 mg single dose and up to 600 mg once daily dosing over 10 days.
Farmakokinetika je linearna po zaužitju enkratnega odmerka v razponu 50 - 800 mg in med desetdnevnim jemanjem do 600 mg enkrat na dan. Koncentracija je največja pol do štiri ure po zaužitju 400 mg peroralnega odmerka in znaša 3,1 mg/l.
Therefore in such cases empirical moxifloxacin should be co-administered with another appropriate antibiotic (e.g. a cephalosporin) unless moxifloxacin-resistant Neisseria gonorrhoeae can be excluded.
V takšnih primerih je treba moksifloksacin uporabiti empirično hkrati z drugim ustreznim antibiotikom (npr. cefalosporinom), razen če je mogoče izključiti prisotnost proti moksifloksacinu odporne bakterije Neisseria gonorrhoeae.
Moxifloxacin is eliminated from plasma with a mean terminal half life of approximately 12 hours.
Povprečna končna razpolovna doba izločanja moksifloksacina iz plazme je približno 12 ur.
Bayer HealthCare AG 51368 Leverkusen Germany
Bayer HealthCare AG 51368 Leverkusen Nemčija
It is approved for the treatment of the following bacterial infections if they are caused by bacteria susceptible to moxifloxacin: - Acute exacerbation of chronic bronchitis - Community acquired pneumonia, except severe cases - Acute bacterial sinusitis (adequately diagnosed).
Zdravilo je odobreno za zdravljenje spodaj naštetih bakterijskih okužb, če jih povzročajo bakterije, občutljive na moksifloksacin: - akutnega poslabšanja kroničnega bronhitisa, - zunajbolnišnične pljučnica, razen v hudih primerih, - akutnega bakterijskega sinuzitisa (ustrezno diagnosticiranega).
- Taking oral medicinal charcoal at the same time as [Invented name] tablets reduces the action of [Invented name].
- Ker sočasno peroralno jemanje aktivnega oglja in tablet [izmišljeno ime] zmanjšuje delovanje zdravila [izmišljeno ime], sočasne uporabe ne priporočamo.
Concomitant administration of moxifloxacin with ranitidine or probenecid did not alter renal clearance of the parent drug.
Pri sočasni uporabi moksifloksacina in ranitidina ali probenecida se ledvični očistek prvotne učinkovine ni spremenil.
No adjustment of the dose is required in elderly patients, patients with a low bodyweight or in patients with kidney problems.
Starejšim bolnikom, bolnikom z majhno telesno maso in bolnikom z ledvičnimi težavami odmerka ni treba prilagajati.
3 from 3 h up to 36 h post dose 4 at the end of infusion
2 koncentracija nevezane učinkovine 3 3 do 36 ur po odmerku
In clinical practice, this would mean that moxifloxacin should be used in combination with an approved agent active against fluoroquinolone resistant N. gonorrhoeae (e.g. a cephalosporin) for empirical treatment of PID unless moxifloxacinresistant N. gonorrhoeae can be excluded.
V klinični praksi bi to pomenilo, da se moksifloksacin uporablja v kombinaciji z odobreno učinkovino proti N. gonorrhoeae, odporno na fluorokinolone, (npr. cefalosporinom) za empirično zdravljenje pelvičnih vnetnih bolezni, razen če je mogoče izključiti N. gonorrhoeae, odporno na moksifloksacin.
The magnitude of QT prolongation may increase with increasing concentrations of the drug.
Ker se z naraščajočimi koncentracijami zdravila dolžina podaljšanja dobe QT lahko poveča, se priporočenega odmerka ne sme prekoračiti.